IL2 and neoplasm: Additional studies have demonstrated that low levels of CD57+ NK cells were found to be an independent immune risk factor affecting the prognosis of mRCC patients treated with IL-2, indicating that activated NK cells may be critical for IL-2 to exert its anti-tumor activity (58).